Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study

Table 3 Univariable regression analysis of potential risk factors for fat abnormalities in the Maggsen cohort study^a, Dakar, Senegal

Characteristics	Lipoatrophy			Fat abnormality
Characteristics	OR	95% CI	P value	OR	95% CI	P value
Boys	4.3	1.6–11.6	0.004	2.7	1.2–6.3	0.02
Age ≥ 10 years	1.3	0.6–2.9	0.54	1.4	0.6–3.0	0.42
Puberty onset: Yes	1.2	0.5–2.7	0.64	1.3	0.6–2.7	0.52
Moderate wastingb: Yes	1.7	0.7–3.9	0.20	1.4	0.6–3.1	0.43
WHO classification Stage^c 3/4 vs 1/2	1.7	0.5–5.0	0.37	2.0	0.7–5.8	0.23
Viral load > 40 copies/mL: Yes	1.1	0.5–2.6	0.76	0.9	0.4–2.0	0.82
CD4 < 500 cells/mm³: Yes	0.5	0.1–1.7	0.26	0.6	0.2–1.8	0.34
Stavudine ever used: Yes	2.1	0.9–5.2	0.09	2.1	0.9–5.0	0.08
Stavudine exposure 1 year vs No	1.5	0.5–4.8	0.48	1.7	0.6–4.9	0.32
≥1 year vs No	3.6	1.0–12.6	0.04	3.1	0.9–10.8	0.07
Zidovudine recent: Yes	1.0	0.4–2.4	0.94	1.0	0.4–2.3	0.93
Zidovudine exposure < 3 years vs No	0.5	0.2–1.8	0.30	0.6	0.2–1.7	0.30
≥3 years vs No	1.3	0.5–3.3	0.61	1.2	0.5–3.0	0.63
Lopinavir/r recent: Yes	1.3	0.6–3.1	0.51	1.1	0.5–2.5	0.86
Lopinavir/r exposure < 3 years vs No	0.3	0.0–2.5	0.28	0.3	0.0–2.0	0.20
≥3 years vs No	2.2	0.9–5.4	0.09	1.8	0.7–4.3	0.21

^aAbbreviations: CI confidence interval, Lopinavir/r lopinavir/ritonavir, OR odds ratio
^bModerate wasting (moderate acute malnutrition) is defined for both weight-for-height z scores (WHZ) in children < 5 years or body mass index-for-age z score (BMIZ) in children ≥5 years as being ≥ − 3 and < − 2 [20, 21]
^cWHO symptoms classification: highest stage reached by the child before ART initiation

ISSN: 1471-2334